The data, which covers the period between July and September ... up slightly from its previous forecast. Pharmaceuticals ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization ...

Companies such as Procter & Gamble, and GSK, were among several accused in lawsuits of deceiving consumers about cold medicines containing the ingredient. The FDA is now seeking public comments on ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an expansion project that would add research and manufacturing capabilities ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020 ... for Morningstar*. He covers Life Science Tools and Diagnostics companies as well as large Japanese drugmakers ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...